clonoSEQ[®] By Adaptive

Multiple myeloma. CLL. B-ALL. It's a journey. **PINPOINT WHERE YOUR BLOOD CANCER STANDS WITH clonoSEQ®**.

clonoSEQ (pronounced clo-no-seek) is the first and only FDA-cleared test that detects, counts, and tracks minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lympoblastic leukemia (B-ALL) and blood or bone marrow samples from patients with chronic lymphocytic leukemia (CLL).¹

How does clonoSEQ work?

clonoSEQ identifies the specific DNA sequence(s) associated with your cancer and tracks them over time. clonoSEQ can detect one single cancer cell among a million healthy cells (provided sufficient sample material). To do this, clonoSEQ:¹



How can clonoSEQ results help shape your care plan?

The results from MRD testing with clonoSEQ, along with other clinical information, may help your doctor tailor your care to changes in your disease level.²⁻⁴ **Talk with your doctor to find out if a goal of MRD negativity is right for you.**

Why is ongoing clonoSEQ testing useful?

clonoSEQ gives you and your doctor a personalized way to track—and talk about—your body's individual response to treatment. **Regular MRD testing can give you and your doctor the information to make informed decisions at each stage of treatment.**

Why should I test when I'm not experiencing any symptoms?

Even if you aren't experiencing any symptoms, you may still feel anxious or worried that the cancer will return. Routine MRD testing may help detect the return of cancer before physical signs and symptoms arise, so you and your doctor can respond—and plan for the future.

References to "cancer" refer specifically to multiple myeloma, CLL, and B-ALL. References to "sample" refer to bone marrow from patients with multiple myeloma or B-ALL and bone marrow or blood from patients with CLL. Talk to your doctor about your options if you have another type of blood cancer and are interested in MRD testing.

What does your clonoSEQ report mean?

Adaptive Biotechnologies delivers MRD results from your clonoSEQ test to your doctor as a report. Your doctor considers the information in this report along with your physical examination, your medical history, and other test results and findings.

Be sure to talk with your doctor about the optimal timing for MRD testing with clonoSEQ based on the type of blood cancer you have and your specific treatment plan.

	iagnostic Use. Rx Only.	1					
ATIENT NAME ane McDoe		DATE OF BIRTH 01/02/2000	MEDICAL RECOR 123456	D#	GENDER Female	REPORT DATE 01/10/2018	ORDER# D-101424
ECIMEN TYPE / SPECIMEN SOURCE		COLLECTION DATE 01/02/2018	DATE RECEIVED 01/03/2018		SAMPLE ID SP-101099 (19-BM-0035)		
CODE 1.00 Acu	te lymphoblastic leukemi	a not having achieved remi	ssion				
RDERING PHYSICIAN Javandar Smith			INSTITUTION		resital		
	VEL MRD RESULT		Unive	sity cancer Ho	зрка		
+	Residual Seq ESTIMATED MRD VALU 8 residual clon Total nucleated cells e	uences Detecte E: al cells per million valuated from this sample:	ed nucleated c 1,913,001	ells (Range	e: 3 - 13)		
evaluat The re and ot	ted from this sample. sults obtained from thi her findings. VEL MRD TRACKING (sh	s assay should always be ows only the sequence det	used in combination	tion with the	clinical exar	nination, patient i	medical history
evaluat The re and ot MPLE-LE	ted from this sample. sults obtained from thi her findings. IVEL MRD TRACKING (sh	s assay should always be ows only the sequence det	used in combina	tion with the	clinical exar	nination, patient i	medical history
evaluar The re and ot MPLE-LE 1 10 ⁻¹	ted from this sample. sults obtained from thi her findings. VEL MRD TRACKING (st	s assay should always be aws only the sequence det	used in combini	tion with the	e clinical exar	nination, patient i	medical history
evaluar The re and ot 10 ⁻¹	ted from this sample. sults obtained from thi her findings. VEL MRD TRACKING (st)	s assay should always be ows only the sequence det	used in combina	tion with the	e clinical exar	nination, patient i	medical history
evalua The re and ot MPLE-LE 1 10 ⁻¹ 5 ¹¹⁰ 10 ⁻² 10 ⁻² 10 ⁻³	ted from this sample. sults obtained from thi her findings. VEL MRD TRACKING (st)	s assay should always be	used in combining the MR	tion with the	e clinical exar	nination, patient I	medical history
evaluai The re and ot MPLE-LE 1 10 ⁻¹ 10 ⁻¹ 10 ⁻¹ 10 ⁻² 10 ⁻³ 10 ⁻³ 10 ⁻³	ted from this sample.	s assay should always be one only the sequence det	used in combine	tion with the	clinical exar	nination, patient r	medical history
evalua The re and ot 1 10 ⁻¹ 10 ⁻¹ 10 ⁻¹ 10 ⁻² 10 ⁻³ 10 ⁻³ 10 ⁻⁴ 10 ⁻⁵	eted from this sample. suits obtained from thi her findings. VEL MRD TRACKING (s/	s assay should always be one only the sequence det	ermining the MR	tion with the	e clinical exar	nination, patient r	medical history
evalua The re and ot 1 10 ⁻¹ 10 ⁻¹ 10 ⁻¹ 10 ⁻² 10 ⁻³ 10 ⁻² 10 ⁻³ 10 ⁻² 10 ⁻³ 10 ⁻⁴ 10 ⁻³	ted from this sample.	s assay should always be ones only (the sequence def	ermining the MR	tion with the	clinical exar	nination, patient r	medical history
evalua The re and ot 1 10 ⁻¹ 10 ⁻¹ 10 ⁻¹ 10 ⁻¹ 10 ⁻² 10 ⁻² 10 ⁻³ 10 ⁻⁴	eef from this sample. Suits obtained from thi her findings. VEL MRD TRACKING (2)	s assay should always be	ermining the MR	tion with the	c clinical exam	nination, patient of	medical history
evalual The re and ot 1 10 ⁻¹ 10 ⁻² 10 ⁻² 10 ⁻³ 10 ⁻⁶	et from this sample. subt sobained from thi her findings. VEL MRD TEACHING (s) NEL MRD TEACHING (s) (1777) -M- Bone Marrow	a assay should always be and any the experiment and a start of the experiment and a start of the start of the start of the Constity Text: Idl. Sequence	ermining the MR	n Date hence intervals	c clinical exar ch time point)	nination, patient i	medical history
evaluat The re and ot 1 10 ⁻¹ 10 ⁻¹ 10 ⁻¹ 10 ⁻¹ 10 ⁻² 10 ⁻⁵ 10 ⁻⁶	et from this sample. NUEL MRD TRACKING (A) NEL MRD TRACKING (A) M M (1777) -M- Bune Marree Tracking Test 16 51	a assay should always be and only the acquerce data and a start of the acquerce data and a start of the acquerce data Consulty Tett: IGL Sequence appender C	erminag the 1/2 erminag the 1/2 ermina	N DATE ence Intervals	e clinical exar ch time point)	nination, patient n	medical history
evaluai The re and ot MPLE-LE 1 10 ⁻¹ 10 ⁻² 10 ⁻² 10 ⁻² 10 ⁻² 10 ⁻⁴ 10 ⁻⁴	eted from this sample. NUEL MARIA from this NEL MARIA TO ACKING (A) NUEL MARIA (A) NUEL MARIA (A) NUEL MARIA (A) (A) (A) (A) (A) (A) (A) (A)	a assay should always be rear and phy the appended did and any the appended did appended to appended did Counting Text: ISL - Sequence equence C 1 yyee A such, changes in closel of	erminage the 1/3 erminage the 1/3 under 1/3 erminage the	tion with the	e clinical exar ch dime point ch di dime point ch dime point ch dime point c	Initiation, patient en	medical history

clonoSEQ report will be individual to you.

*False-positive or false-negative results may occur for reasons including, but not limited to: contamination, technical, and/or biological factors.

See what a clonoSEQ report includes

clonoSEQ is sensitive enough to find a single cancer cell among a million healthy cells, if enough sample material is provided.¹

1 clonoSEQ MRD Status

A positive (+) result means residual disease was detected. A negative (-) result means residual disease was not detected. Each report will provide your updated MRD status.* You can gain valuable insights about your cancer regardless of whether you have a positive or negative result. **Talk to your doctor about your MRD status to better understand what a positive or negative result means for you and your treatment plan.**

2 MRD Level

This is the amount of cancer cells detected in your sample. This number shows how much disease is present in your sample when it is taken. **Your doctor can help put this number into context based on your current phase of care and treatment goals.**

3 MRD Trend

1 of 5

A simple graph will show any changes detected in your MRD level over time. Watching these changes may help you and your doctor better understand your response to treatment and track changes in your cancer over time.



Please visit <u>clonoSEQ.com/patients</u> for more information

clonoSEQ® is an FDA-cleared test used to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.

1. clonoSEQ[®]. [technical summary]. Seattle, WA: Adaptive Biotechnologies; 2020. 2. Martinez-Lopez J, et al. *J Hematol Oncol.* 2021;14(1):126. 3. Friend B, et al. *Pediatr Blood Cancer.* 2020;67(2):e28079. 4. Al-Sawaf O, et al. *J Clin Oncol.* 2021;JCO2101181.

